Ribomic, Inc. (4591) AI Stock Analysis

• Market Cap: ¥5.16B
• Dividend Yield: N/A
• Average Volume (3M): 477.44K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.62
• Revenue Growth: -100.00%
• EPS Growth: 7.60%
• Country: JP
• Employees: 24
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -4.67
• Shares Outstanding: 54,332,640
• 10 Day Avg. Volume: 531,790
• 30 Day Avg. Volume: 477,440
• PEG Ratio: 0.32
• Price to Book (P/B): 1.30
• Price to Sales (P/S): 1880.02
• P/FCF Ratio: -3.84
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 47 Neutral
• Price Target: ¥85.00 ▲(13.33% Upside)
• Action: Reiterated Date: 03/05/26
• Date: Action: Reiterated 03/05/26

The score is held down primarily by weak financial performance—very small/volatile revenue, large ongoing losses, and persistent cash burn—despite a debt-free balance sheet. Technicals are moderately supportive in the short term (price above shorter moving averages) but are tempered by overbought signals and a price still below the 200-day average. Valuation provides limited support due to negative earnings and no dividend yield data.

Positive Factors

Debt-free balance sheet

Maintaining no debt is a durable defensive advantage: it lowers refinancing risk and interest burden, preserving strategic optionality while the business develops. For a cash-burning biotech, being debt-free lengthens runway flexibility and reduces forced capital-structure constraints.

Positive gross profit where revenue exists

Consistent positive gross margins when revenue occurs indicate the company can generate unit-level margin on sales. If management can scale revenue and rein in operating costs, these underlying margins provide a realistic path to improving operating leverage and eventual profitability.

Cash flow aligns with accounting losses

FCF tracking net losses implies cash burn is driven mainly by operating losses rather than large non-cash or irregular charges. This makes cash needs more predictable, aiding planning and allowing management to better align funding strategies and cost reductions to actual operational performance.

Negative Factors

Minimal, volatile revenue

The absence of stable revenue shows a lack of commercial traction and reliance on irregular income or one-offs. Structural revenue weakness limits operating scalability, makes forecasting unreliable, and means large fixed costs will continue to overwhelm the business until consistent top-line growth is achieved.

Large, persistent cash burn

Sustained ~¥1.0B annual cash outflow versus negligible revenue creates an ongoing funding requirement. Over months this drives dilution risk, constrains investments in R&D/commercialization, and forces management to prioritize financing over long-term strategic initiatives absent a clear path to cash generation.

Erosion of shareholder equity

Material equity decline reflects accumulated losses and possible dilution, signaling balance-sheet erosion. Persistent negative returns on equity reduce strategic flexibility, increase vulnerability to funding shocks, and raise the bar for future capital raises to avoid solvency stress as cash reserves deplete.

Ribomic, Inc. Business Overview & Revenue Model

Company Description

Ribomic Inc. discovers and develops pharmaceutical compounds using RNA aptamers in Japan. The company develops drugs for wet age-related macular degeneration, achondroplasia, pulmonary arterial hypertension, proliferative vitreoretinopathy, heart failure, osteoarthritis, and asthma, as well as separating agents for affinity purification of human IgG and Fc-fusion proteins. Ribomic Inc. was incorporated in 2003 and is headquartered in Tokyo, Japan.

How the Company Makes Money

Ribomic, Inc. generates revenue primarily through research and development partnerships, licensing agreements, and potential milestone and royalty payments associated with its aptamer-based therapeutics. The company collaborates with pharmaceutical and biotechnology firms to co-develop and commercialize its drug candidates, leveraging its proprietary technology platform. These partnerships often involve upfront payments, as well as contingent payments based on the achievement of specific development, regulatory, or sales milestones. Additionally, once the products are commercialized, Ribomic stands to earn royalties based on sales, further contributing to its revenue.

Ribomic, Inc. Financial Statement Overview

Summary

Financial performance is weak: revenue is minimal and volatile (including a drop to zero in FY2024), losses are large and worsening again in FY2025, and cash burn remains substantial (FY2025 operating cash flow about -¥1.0B and free cash flow about -¥1.03B). The main offset is a debt-free balance sheet, though equity has declined materially over time.

Income Statement

Revenue is small and volatile, including a drop to zero in FY2024 and only ~¥2.1M in FY2025, indicating limited commercial scale and/or dependence on irregular sources. Profitability is deeply negative across the period, with losses widening again in FY2025 (net loss ~¥1.02B) and extremely weak margins given the low revenue base. A positive is that reported gross profit is generally positive (where revenue exists), but operating costs overwhelm the business model at its current stage.

Balance Sheet

The company reports no debt across all years, which reduces financial risk and refinancing pressure. However, equity has declined materially over time (from ~¥6.0B in FY2021 to ~¥3.0B in FY2025), consistent with ongoing losses and dilution/erosion of capital. Returns on equity are persistently negative, highlighting that the balance sheet strength is being consumed rather than compounded.

Cash Flow

Cash burn is substantial and persistent, with operating cash flow negative every year (about -¥1.0B in FY2025) and free cash flow also negative (about -¥1.03B in FY2025). While free cash flow improved in FY2024 versus FY2023, it deteriorated again in FY2025, suggesting an uneven but ongoing funding requirement. A modest positive is that free cash flow roughly tracks net loss (cash burn not dramatically worse than accounting losses), but the absolute level of burn remains high versus the revenue base.

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	1.11M	2.11M	0.00	65.97M	80.91M	91.96M
Gross Profit	-190.00K	2.11M	-10.50M	65.97M	80.91M	91.96M
EBITDA	-992.17M	-1.02B	-1.01B	-1.79B	-1.73B	-1.21B
Net Income	-992.39M	-1.02B	-1.02B	-1.65B	-1.68B	-1.19B
Balance Sheet
Total Assets	2.93B	3.19B	3.55B	4.58B	4.95B	6.12B
Cash, Cash Equivalents and Short-Term Investments	2.81B	3.04B	3.40B	4.33B	4.70B	5.84B
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00
Total Liabilities	111.84M	142.21M	155.81M	199.30M	260.53M	116.96M
Stockholders Equity	2.82B	3.04B	3.39B	4.38B	4.69B	6.00B
Cash Flow
Free Cash Flow	0.00	-1.03B	-955.48M	-1.73B	-1.51B	-1.15B
Operating Cash Flow	0.00	-999.00M	-932.76M	-1.71B	-1.50B	-1.15B
Investing Cash Flow	0.00	67.18M	177.27M	276.35M	689.56M	-1.70B
Financing Cash Flow	0.00	667.26M	27.65M	1.33B	354.72M	4.99B

Ribomic, Inc. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 75.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4591, the sentiment is Positive. The current price of 75 is below the 20-day moving average (MA) of 86.60, below the 50-day MA of 85.06, and below the 200-day MA of 92.61, indicating a bullish trend. The MACD of 2.53 indicates Negative momentum. The RSI at 60.78 is Neutral, neither overbought nor oversold. The STOCH value of 36.27 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4591.

Ribomic, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4571	52 Neutral	¥12.81B	-12.44	-26.70%	―	172.39%	8.27%
2183	52 Neutral	¥7.02B	-2.65	―	5.44%	-15.42%	-879.08%
4974	52 Neutral	¥138.00B	-8.84	―	2.18%	-0.16%	-802.20%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
4575	51 Neutral	¥15.14B	-17.96	―	―	―	14.03%
4591	47 Neutral	¥5.16B	-4.17	―	―	-100.00%	7.60%
4587	46 Neutral	¥189.35B	-57.13	-10.16%	―	-62.47%	-134.06%

Ribomic, Inc. Corporate Events

RIBOMIC Posts Continued Losses but Maintains Strong Equity Base in Nine-Month Results

RIBOMIC Inc. reported non-consolidated results for the nine months to December 31, 2025, with operating revenue effectively at zero and a net loss of ¥763 million, though the per-share loss narrowed from ¥18.88 to ¥15.86 year on year. Total assets rose to ¥3.38 billion and the equity ratio remained high at 94.2%, but the company continues to suspend dividends and forecasts a full-year loss of ¥1.28 billion on modest revenue of ¥3 million.

The biotech firm’s persistent losses underscore the long development timelines and funding demands typical of early-stage drug discovery companies, even as its strong equity ratio suggests a still-solid balance sheet. Shareholders face continued dilution risk, with issued shares rising to 54.3 million, and no near-term income returns, as management maintains a zero-dividend policy while prioritizing R&D and long-term pipeline value creation.

The most recent analyst rating on (JP:4591) stock is a Hold with a Yen83.00 price target. To see the full list of analyst forecasts on Ribomic, Inc. stock, see the JP:4591 Stock Forecast page.

Ribomic Files Patent for High-Activity Eye-Disease Aptamer RBM-006 After Positive Diabetic Retinopathy Data

Ribomic has filed a new substance patent application in Japan for RBM-006, a highly active anti-autotaxin aptamer with a shorter chain length than existing candidates, and reported that the molecule significantly suppressed retinal hemorrhage in a mouse model of diabetic retinopathy. The data, generated in collaboration with the University of Tokyo, strengthen the intellectual property position around RBM-006 and underscore its potential as a mechanistically distinct alternative to anti-VEGF drugs, which fail to benefit more than half of diabetic retinopathy patients, with the company planning to pursue early commercialization through partnerships while confirming that funding for development is secured and its full-year earnings forecast remains unchanged.

The most recent analyst rating on (JP:4591) stock is a Hold with a Yen84.00 price target. To see the full list of analyst forecasts on Ribomic, Inc. stock, see the JP:4591 Stock Forecast page.